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The Role of Endothelin Receptor A during Myelination of 
Developing Oligodendrocytes
Endothelin (ET)-1 and its receptors (ETA and ETB receptor) are present in the central nervous 
system. ET exerts biological effects on gliogenesis and glial cell functions. In order to define 
a possible mechanism of ETA receptor signaling, the distribution of the ETA receptor in 
developing oligodendrocytes and the effects of ET-1 on the myelination of 
oligodendrocytes were examined. ETA receptor immunoreactivity was confined to the 
perivascular elements of the blood vessels during early postnatal development. However 
later in development, ETA receptor immunoreactivity was no longer observed in the vessels 
but became localized to the myelinating oligodendrocytes of the primitive corpus callosum 
of the white matter, apart from the vessels. ET-1 induced myelin basic protein (MBP) in 
primary oligodendrocyte precursor cell culture though the ETA receptor and was blocked 
by an ETA receptor antagonist. In addition, ET-1 evoked the release of Ca
2+ which is a 
central regulator of oligodendrocyte differentiation. Our results provide a link between 
ET-1 and its ETA receptor and myelination during oligodendrocyte differentiation.
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Neuroscience
INTRODUCTION
The endothelins (ETs) are 21 amino acid peptides that were 
originally cloned from bovine aortic endothelial cells (1) and 
that are expressed as three biologically active peptides: ET-1, 
ET-2, and ET-3. ETs are expressed by a variety of cell types in-
cluding endothelial cells, macrophages, astrocytes, and neu-
rons (2). ET isoforms act through the G protein-coupled recep-
tors, the endothelin A (ETA) receptor and the endothelin B 
(ETB) receptor. Different ET peptides modulate the develop-
ment of distinct neural cell types including Schwann cells (3), 
astrocytes (4), and neural crest cells (5) as well as physiologic 
renal growth and development (6). ET receptor expression is 
regulated during neural cell maturation. Each ET isoform can 
act through both of the receptors but the receptors have differ-
ent affinities for each of the 3 isoforms. The ETA receptor has a 
greater affinity for ET-1 and the ETB receptor binds to all 3 pep-
tides equally (7). This distinction between ligand binding and 
receptor activation is thought to contribute to the diversity of 
their physiological responses (8, 9).
  The findings that ETs exert biological effects on gliogenesis 
and glial cell function raise the important question of whether 
this peptide might affect oligodendrocyte development. Oligo-
dendrocytes are thought to originate in a restricted ventricular 
zone of the ventral neural tube and then migrate to their final 
destinations and mature there (10). Recently, Gallo and col-
leagues (11) reported that ET-1 is a soluble astrocyte-derived 
signal that can regulate the migration and developmental dif-
ferentiation of oligodendrocyte precursor cells (OPCs). Howev-
er, they did not show the specific stages of regulation on OPC 
differentiation and related signaling pathways. In addition, the 
role of ET-1 on models of autoimmune demyelination like ex-
perimental autoimmune encephalomyelitis (EAE) was studied 
by blocking the action of ET-1 with an ETA receptor antagonist, Jung KJ, et al.  •  ETA Receptor-mediated Oligodendrocyte Precursor Cell Myelination
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BQ-123. Intrathecal administration of BQ-123 significantly ame-
liorates EAE progression at its peak stage (12). 
  In this study, in order to define a possible role for ET-1 in oli-
godendrocyte development, we morphologically examined 
ETA receptor expression during each stage of oligodendrocyte 
development and the functional role of ETA receptor in oligo-
dendrocyte myelination.
MATERIALS AND METHODS
Immunohistochemistry and double immunofluorescence
Brains were removed from ICR mice (Samtako, Osan, Korea) on 
postnatal day (P) 1 and 1, 2, 4, and 8 weeks of age (i.e., P1d, P1w, 
P2w, P4w and P8w, n = 5 in each group), and then fixed in 4% 
paraformaldehyde in phosphate buffered saline (PBS) at pH 7.4 
for 2 hr. All animal experiments were approved by the Institu-
tional Animal Care and Use Committee in Chungnam National 
University (2009-3-17). The tissue was cryoprotected by infiltra-
tion with a 10%-30% sucrose solution, embedded in an Optimal 
Cutting Temperature compound, and then rapidly frozen in 2- 
  methyl butane precooled to its freezing point with liquid nitro-
gen. Tissue specimens were cut into 10 µm sagittal or horizontal 
sections on a cryostat and then mounted. Immunohistochemi-
cal staining of the tissue sections was done using the avidin-bi-
otin peroxidase complex (ABC) method described previously 
(13). Sections were treated with blocking buffer (1% fetal bovine 
serum and 0.3% Triton X-100 in PBS) for 30 min after endoge-
nous peroxidase blocking with 1% H2O2 in PBS and then rinsed 
thoroughly with PBS. Sections were incubated with the primary 
antibody for 24 hr at 4°C. The antibodies and their dilutions were 
ETA receptor (anti-rabbit, Sigma, St. Louis, MO, USA, E3651, 
1:100), CD31 (anti-rat, BD Biosciences, Frankin Lakes, NJ, USA, 
550274, 1:500), myelin basic protein (MBP, anti-rat, Millipore, 
Billerica, MA, USA, MAB386, 1:100), and adenomatous polypo-
sis coli protein (APC, anti-mouse, Merck, Darmstadt, Germany, 
OP80, 1:500). Tissues were exposed to the biotinylated anti-mo-
use IgG and the streptavidin peroxidase complex (Vector labs, 
Burlingame, CA, USA) for 1 hr at room temperature after rins-
ing with PBS. Immunostains were visualized with diaminoben-
zidine (DAB, Sigma) for 3-5 min and then mounted using Poly-
mount. Double immunofluorescent experiments were done 
using Cy
TM2-conjugated anti-rabbit IgG (1:400) and Cy
TM3-con-
jugated anti-mouse IgG (1:600, Amersham, Buckinghamshire, 
UK). All immunoreactions were examined under a fluorescent 
microscope (IX71, Olympus, Tokyo, Japan).
Oligodendrocyte precursor cell culture
We prepared primary OPC cultures by mechanical dissociation 
according to the method by Chen et al. (14). Briefly, a P1 Spra-
gue-Dawley rat pup (Samtako, Osan, Korea) was decapitated in 
an ice-chilled dish and the brain was removed. Mixed cultures 
were shaken overnight to detach OPCs from the astrocyte mo-
nolayer. Oligodendrocyte progenitors were plated on poly-D-
lysine-coated culture dishes and grown in basal defined media 
(BDM) consisting of DMEM20S (DMEM, 4 mM L-glutamine, 1 
mM sodium pyruvate, 20% FBS), 0.1% bovine serum albumin, 
50 µg/mL human transferrin, 10 nM hydrocortisone, 10 nM bi-
otin, 5 µg/mL insulin and 30 nM selenium. After stabilization of 
the oligodendrocyte progenitor cells for 3 days, 20 ng/mL each 
of PDGFAA and bFGF (Peprotech, Rocky Hill, CT, USA) were 
added to the media to differentiate the OPCs which were used 
after 3 days in vitro (DIV). The cultured cells were characterized 
immunocytochemically with cell-type-specific antibodies. More 
than 95% of the cells were positive for the monoclonal antibody 
A2B5 (clone 105, IgM, R&D systems, Minneapolis, MN, USA) 
and for the PDGFA receptor (CD140a, Millipore), a marker for 
OPCs in culture, while less than 5% of the cells were GalC-posi-
tive OLGs, GFAP-positive astrocytes or complement type-3-pos-
itive microglia (15, 16).
Reverse transcription Polymerase Chain Reaction  
(RT-PCR)
Total RNA was extracted from cultured OPCs using TRizol (In-
vitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
protocol. The amount of RNA and its purity was determined by 
measuring the optical density at 260 nm and the optical density 
ratio at 260 and 280 nm (ratio ~ 2), respectively. RNA integrity 
was checked by electrophoresis on agarose gel. Approximately 
10 µg of total RNA from each sample was used to generate cDNA 
in a 40 µL reaction using 200 U of the SuperScript II (Invitrogen, 
Carlsbad, CA, USA) reverse transcriptase and oligo (dT). Subse-
quently, 2 µL of cDNA was subjected to PCR amplification in 
order to measure the expression of MBP gene. To amplify rat 
MBP, we used the following forward primer: 5´-CTGCCCTCG-
GCTTCTTAAT-3´ (456–474) and reverse primer 5´-GTTTTAG-
CCAGTCAGGGTGC-3´ (576–595). The nucleotide position re-
ported in brackets corresponded to the published rat MBP cDNA 
sequence (GenBank accession number, M25889). Genes were 
amplified as follows: denaturation at 94°C for 1 min, annealing 
at 60°C for 1 min, extension at 72°C for 1 min, and this was re-
peated for 28 cycles. PCR products were resolved by 1.2% aga-
rose gel electrophoresis and visualized under UV light.
Western blot analysis
At P1d, P1w, P2w, P4w and P8w, the ICR mice (Samtako) were 
anesthetized. The entire brain was removed quickly from each 
mouse and homogenized in lysis buffer (50 mM TrisCl, 150 mM 
NaCl, 0.02% sodium azide, 100 µL/mL PMSF, 1 µg/mL aprotinin, 
1% Triton X-100). Supernatant protein concentrations were de-
termined with Micro BCA protein assay kits. Bovine serum albu-
min was used as a standard (Pierce Chemical, Rockford, IL, USA). 
Aliquots containing 20 µg of protein were boiled in 2 × sample Jung KJ, et al.  •  ETA Receptor-mediated Oligodendrocyte Precursor Cell Myelination
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buffer (0.8 M TrisCl, 10% glycerol, 20% β-mercaptoethanol, 10% 
SDS, and 0.02% bromophenol blue) for 5 min and loaded onto 
a polyacrylamide gel. Proteins were transferred onto nitrocellu-
lose membranes after electrophoresis at 250 mA for 1 hr. Mem-
branes were incubated in 5% skim milk in PBST (0.3% Triton 
X-100 in PBS) for 1 hr to block non-specific binding and then 
probed with a primary antibody: ETA receptor (1:500), MBP 
(1:500), and β-actin (1:5,000, Sigma). Membranes were washed 
3 times for 10 min in PBST and incubated for 1 hr with a peroxi-
dase-labeled secondary antibody (Vector Labs, Burlingame, CA, 
USA) diluted 1:2,000 in PBST. Immunolabeled proteins were 
detected by chemiluminescence after 3 additional washes us-
ing a Supersignal ECL kit (Pierce Chemical, Rockford, IL, USA) 
and Biomax Light-1 films. For blotting of OPCs, cells were treat-
ed with ET-1 and/or BQ123 and then harvested and cell extracts 
were obtained as above. Primary antibodies for ETA-receptor 
(1:500) and MBP (1:500) were used and detected as above.
Intracellular Ca
2+ measurements
OPCs grown on coverslips were loaded with the Ca
2+ indicator 
Fura-2/AM according to the manufacturer’s instructions (Mo-
lecular Probes, Carlsbad, CA, USA). Images were obtained by 
confocal microscopy (Zeiss LSM510 Meta; Carl Zeiss, Jena, Ger-
many). For kinetic measurements, Ca
2+-free HBSS buffer solu-
tion containing 10 mM EGTA was used to eliminate the extra-
cellular Ca
2+, and images were obtained every 5 sec for 15 min at 
37°C using a Cool-SNAP microscope (HQ, Photometrics, Tuc-
son, AZ, USA).
RESULTS
ETA receptor expression in oligodendrocyte lineage cells 
in vivo
During early development (P1d), ETA receptor immunoreactiv-
ity has been associated with blood vessels (Fig. 1A). However 
later in development, ETA receptor immunoreactivity was no 
longer observed in the vessels but became localized to the round 
oligodendrocyte-like cells of the corpus callosum and the white 
matter, apart from the vessels (Fig. 1B-D). MBP immunoreac-
tivity was weakly found in the primitive corpus callosum region 
and then intensified in the corpus callosum during later devel-
opment (Fig. 1E-H). ETA receptor immunoreactivity was ob-
served on the exterior surface of blood vessels and appeared as 
small, oval cell bodies with processes that extended for some 
Fig. 1. ETA receptor and MBP immunoreactivity with cresyl violet counterstain in the developing mouse brain. Ages examined were P1d (A, E, I), P1w (B, F, J), P2w (C, G, K), 
and P4w (D, H, L). During early development (P1d), ETA receptor immunoreactivity was associated with blood vessels (A). However at a later point in time, ETA receptor immu­
noreactivity disappears from the vessels (arrowheads in B), and is instead localized within round oligodendrocyte­like cells in the corpus callosum (CC) (C, D). MBP immu­
noreactivity appears at P1w in the primitive corpus callosum (arrows in F) and is strongly expressed in the corpus callosum later (G, H). Higher magnification of the rectangular 
area in A shows the perivascular expression of the ETA receptor (white arrowhead in I) at P1d, but ETA receptor immunoreactivity appears in primitive corpus callosum (arrows 
in J) and increases with development in oligodendrocyte­like cells of the white matter (K, L). Scale bar = 100 µm in A­H, 20 µm in I­L.
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distance parallel to the vessel axes (Fig. 1I). To examine the lo-
calization of the ETA receptor in the perivascular elements of 
the vessels, double labeling with the ETA receptor and CD31, a 
marker of endothelial cells, was done. The ETA receptor was as-
sociated with blood vessels, but its perivascular elements were 
found to not co-localize with CD31, suggesting that the ETA re-
ceptor was expressed in the perivascular cells during early de-
velopment (Fig. 2A-C). Since ETA receptor immunoreactivity 
was found in the primitive corpus callosum, double labeling 
with MBP, a marker of mature oligodendrocytes, was done. The 
ETA receptor co-localized with MBP positive cells at P1w (Fig. 
2D-F) and the amount of ETA receptor-positive labeling in oli-
godendrocytes was higher at later stages of development. In 
addition, labeling with the other oligodendrocyte marker APC 
was also confirmed (Fig. 2G-I). Western blot was done to exam-
ine changes in the ETA receptor and MBP levels. Intense ETA 
receptor bands were detected at P1d and the intensity of these 
bands increased in ages approaching adulthood (P8w). On the 
other hand, MBP levels were found at P2w and they increased 
thereafter. Immunoblots for these ETA receptor proteins in the 
developing brain generally confirm the immunochemical find-
ings (Fig. 3).
ET-1 stimulated OPC myelination
We first examined whether treatment of OPCs with an ETA re-
ceptor agonist, ET-1, would lead to increased oligodendrocyte 
A B C
D E F
G H I
P1d
P1w
P4w
Fig. 2. Fluorescent double label­
ing of the ETA receptor and CD31, 
MBP and APC in the developing 
mouse brain. Double labeling for 
the ETA receptor (A, D, G) and 
CD31 (B), MBP (E) and APC (H) 
was exa  mined at P1d (A­C), P1w 
(D­F) and P4w (G­I). The ETA re­
ceptor is associated with blood 
vessels and the perivascular ele­
ments is co­localized with CD31, 
a marker of endothelial cells (arrow 
in C) during early development. At 
a later point in time, the ETA recep­
tor is co­localized with MBP exp­
ression (arrowheads in F). In addi­
tion, ETA receptor immunoreac­
tivity is found with another mature 
oligo  den  drocyte marker, APC (G­I). 
Scale bar = 20 µm.
ETA receptor
MBP
β-actin
P1d
21 kDa
16 kDa
P2w P1w P4w P8w
Fig. 3. Western blots for ETA receptor and MBP expression in mice brains during 
development. This figure shows a representative immunoblot from 3 independent ex­
periments. ETA receptor expression is found at P1d and increased with further deve­
lopment. MBP expression is weakly found at P2w and increased at P4w and P8w. Jung KJ, et al.  •  ETA Receptor-mediated Oligodendrocyte Precursor Cell Myelination
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myelination. OPCs treated with ET-1 exhibited an aggregation 
of cells and induction of MBP which is indicative of myelination 
(Fig. 4). To further examine the effect of ET-1 and ETA receptors 
on the myelination of oligodendrocytes, we measured MBP gene 
A B C
D E F
G H I
24 hrs
48 hrs
Fig. 4. Fluorescent double label­
ing for the ETA receptor and MBP 
in primary OPCs after ET­1 treat­
ment. The ETA receptor was exp­
ressed in a few cells of OPC cul­
tures (A­C). Myelination was asse­
ssed by immunostaining with an 
antibody against MBP, a marker of 
mature oligodendrocytes. OPCs 
were treated with ET­1 (100 nM). 
ETA receptor/MBP positive cells 
increase at 24 and 48 hr after 
treatment with ET­1 (D­I). Scale 
bar = 20 µm.
Fig. 5. Western blot for MBP in primary OPCs after ET­1 treatment alone, or with an ETA receptor blocker. OPCs were treated with ET­1 (100 nM) alone and then preincubated 
with BQ123 (2 µM) for 2 hr before exposure to ET­1. Transcripts (A) and protein (B) of MBP increase after 48 hr of treatment with ET­1 and are blocked by the specific ETA 
receptor antagonist, BQ123. Data are expressed as optical densities and represent means ± SEM of three independent experiments. *P < 0.05.
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expression after 48 hr of treatment with ET-1. The RT-PCR anal-
ysis of MBP mRNA by a MBP-specific primer (17) amplified a 
band of 140 bp. As expected, the application of ET-1 dramatical-
ly increased MBP expression (Fig. 5A). The ET-1 response was 
totally abolished when cells were pretreated with BQ123, an ETA 
receptor antagonist. A relative estimate of PCR products was 
carried out by evaluating the ratio of MBP and the correspond-
ing GAPDH bands for each template. Next, we used a pharma-
cological approach to show that ETA receptors are activated by 
ET-1 during oligodendrocyte myelination. MBP protein was el-
evated with ET-1 and down-regulated with BQ123 (Fig. 5B). The 
data suggest that ET-1 increases the myelination of oligoden-
drocytes by activating the endogenously expressed main ETA 
receptor subtype.
ET-1 simulation promoted OPC myelination through Ca
2+ 
signaling
It has been shown that Ca
2+ signaling is essential in the devel-
opment and functioning of oligodendrocytes. For example, Ca
2+ 
uptake is required for the initiation of myelination (18). There-
fore, we examined the effect of ET-1 on calcium release kinetics 
with a Cool-SNAP microscope. A 4-fold increase in fluorescence 
intensity was detected within 2 min after ET-1 stimulation in 
normal bath solution (HBSS with normal [Ca
2+]), which went 
down immediately and out of phase at 3 min (Fig. 6). This data 
suggests that ET-1 stimulation induces the myelination of oligo-
dendrocytes through Ca
2+ release.
DISCUSSION
In the present study, we investigated the role of the ETA recep-
tor in the myelination of OPCs. Our data showed that the ETA 
receptor is expressed in the capillary wall during early postnatal 
development, but during later development, the ETA receptor is 
expressed in the myelinating oliogodendrocytes. We also dem-
onstrated that ET-1 induces the myelination of oligodendrocytes 
by the ETA receptor and subsequent Ca
2+ release is a central reg-
ulator of ETA receptor-mediated oligodendrocyte myelination.
  Despite the widespread distribution of ET system components 
throughout the brain (19), their function in oligodendrocyte-
lineage cells was unexplored. Gadea et al. (11) reported that ET 
receptors were expressed from the immature oligodendrocyte 
progenitor stage to the differentiated phenotype stage. The con-
stitutive expression of the ETB receptor early in development 
and the upregulation of the ETA receptor under culture condi-
tions which induced OPC differentiation suggest that the ETB 
receptor is expressed as multipotential progenitors and neural 
stem cells whereas the ETA receptor is upregulated in commit-
ted progenitors and their differentiated progenies. However, this 
study did not show the role that the ETA receptor has on specif-
ic stages of oligodendrocyte development in vivo. In this study, 
we clearly showed that the ETA receptor was expressed in my-
elinating oligodendrocytes of the white matter.
  Gallo and colleagues (11) also reported that ET-1 affected 
OPC differentiation by delaying the transition from the O4 to 
the more differentiated O1 stage. In addition, they showed that 
ET-1 reduced MBP and CNP levels at all times in culture and 
promoted migration and decreased the differentiation rate of 
OPCs. However, these findings appear to contrast with our re-
sults. We confirmed several times that ET-1 induced MBP levels 
in OPC cultures. This discrepancy between the previous study 
and our results could be due to the different method of cultur-
ing the OPCs, e.g., the presence or absence of putrescine, pro-
gesterone, T3 hormone, etc., because thyroid treatment initiates 
differentiation of oligodendrocytes into myelinating oligoden-
drocytes (20). In addition, OPCs arise from an overlapping do-
main with the somatic motor neurons and migrate to and ma-
ture in their final microenvironments (10, 21). Migratory OPCs 
are unipolar or bipolar in shape and become highly branched 
in their target region (21, 22). Therefore, ETA receptor expres-
sion in newly emerging myelinating oligodendrocytes in the 
primitive corpus callosum suggests that ETA receptors might 
play an important role in the differentiation of premyelinating 
to myelinating oligodendrocytes.
Fig. 6. Effect of ET­1 on intracellular Ca
2+ release in 
primary OPCs. (A) OPCs were loaded with Fura­2/AM 
and stimulated with ET­1 (100 nM), then imaged by con­
focal microscopy at 1 min intervals. (B) Graphs show 
changes in mean fluorescence intensity from 15 cells 
per microscopic field over time. The figure is represen­
tative of three independent experiments. Fura­2/AM was 
excited with the 340 nm/380 nm, and its fluorescence 
emission was recorded at 510 nm. The actual number 
of cells in each case was approximately 100 single cells.
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  In the normal spinal cord, ETA receptor immunoreactivity is 
found in vascular smooth muscle cells and in a subpopulation 
of primary afferent nerve fibers (23). Moreover in dorsal root 
ganglion and peripheral nerves, ETA receptor immunoreactivi-
ty is present in a subset of small-sized peptidergic and nonpep-
tidergic sensory neurons and their axons and to a lesser extent 
in a subset of medium-sized sensory neurons (24). Since these 
reports about the expression of ETA receptors were different 
with our results, we tested the other antibodies (Alomone Labs, 
Jerusalem, Israel and Research Diagnostics Inc., Flanders, NJ) 
that were used in the above papers. As a result, we found a simi-
lar expression of ETA receptors in the developing oligodendro-
cytes as in our original study.
  Development of oligodendrocytes involves migration of OPCs 
to their final destinations within the CNS, followed by local pro-
liferation, and finally OPCs either differentiate into myelin-form-
ing oligodendrocytes or die by apoptosis (10, 25). These process-
es are regulated by extracellular and axon-dependent factors, 
many of which mediate their actions through multiple Ca
2+-de-
pendent intracellular signaling pathways (26). Downstream tar-
gets of Ca
2+ include extracellular signal-regulated kinases and 
cyclic AMP response element binding protein (CREB), which 
regulate oligodendrocyte cell proliferation, survival, growth, and 
differentiation (27). Extracellular Ca
2+ influx through voltage-
independent Ca
2+ channels plays a critical role in ET-1-induced 
cell proliferation and vascular contraction (28). Biological actions 
of ET-1 are mediated by ETA and ETB which belong to a family 
of G-protein-coupled receptors (7). It has been shown that the 
Gq subfamily induces Ca
2+ entry not only by indirect store-op-
erated mechanisms but also by direct stimulation of cation chan-
nels (29). These results, taken together, suggest that ET-1 might 
induce the differentiation of oligodendrocytes through ETA re-
ceptor-mediated Ca
2+ signaling.
  In this study, we showed that the effects of ETA receptor in 
the myelination of oligodendrocytes act through Ca signaling. 
We suggest that ETA receptor-mediated signaling by ET-1 might 
play a role in oligodendrocyte myelination. Our findings on ET-1 
and oligodendrocyte myelination are important for remyelin-
ation strategies in demyelinating diseases of the central nervous 
system. Although OPCs are present in demyelinated regions, it 
is still undetermined why their differentiation and ability to re-
myelinate are inhibited in diseases such as multiple sclerosis. 
We previously reported that activated CREB is expressed in a 
myelin-associated protein in chicks (13). To elucidate the Ca sig-
naling pathway via protein kinase C and CREB, further research 
is required.
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Factors capable of promoting oligodendrocyte precursor cells (OPCs) differentiation and myelination in vivo is an important 
therapeutic strategy for a variety of pathologies in which demyelination is a component, including multiple sclerosis and spinal 
cord injury. Although OPCs are present in demyelinated regions, it is still undetermined why their differentiation and ability to 
remyelinate are inhibited in diseases such as multiple sclerosis. In this study, we showed that the effects of endothelin A (ETA) 
receptor in the myelination of oligodendrocytes act through Ca signaling. We suggest that ETA receptor-mediated signaling by 
ET-1 might play a role in oligodendrocyte myelination.